BioViva
BioViva is a Seattle-based, privately held biotechnology company developing AAV and CMV gene therapy platforms to treat age-related diseases including dementia, heart disease, and frailty, while pursuing licensing of its IP and operating the CodeKeeper gene therapy database.
- Company typePrivate
- Founded2015
- HeadquartersBainbridge Island, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioViva does
BioViva USA Inc is a privately held biotechnology company founded in 2015 by Elizabeth Parrish, headquartered in Seattle, Washington (Bainbridge Island). The company develops gene therapies that target cellular aging as the root cause of age-related diseases, including heart disease, dementia, diabetes, and frailty. BioViva operates two core gene delivery platforms: a patented AAV (Adeno-Associated Virus) platform with an established safety profile, and a patent-pending CMV (Cytomegalovirus) platform distinguished by its larger genetic payload capacity, enabling multiple therapeutic genes to be delivered in a single treatment. Its therapeutic pipeline includes candidates targeting telomerase (hTERT), klotho, follistatin, PGC-1α, and FGF21 — each addressing distinct hallmarks of aging — with animal studies reporting approximately 41% lifespan extension via the CMV vector and 32% with follistatin.
The company has published research in peer-reviewed venues, including a 2021 human dementia study combining hTERT and Klotho gene therapy in the Journal of Regenerative Medicine and Biology, and a 2022 paper in PNAS demonstrating CMV vector efficacy. CEO Liz Parrish has publicly undergone her own gene therapies twice, establishing the company as a personal-conviction-led venture. The scientific advisory bench includes Harvard geneticist George Church, gerontologist Aubrey de Grey, and biotech entrepreneur Matthew Scholz. Beyond therapeutics, BioViva operates CodeKeeper, an open-access gene therapy database positioned as a community and educational resource.
BioViva's stated revenue model centers on gene therapy drug development and licensing. However, the company has not disclosed revenue, pricing, or material commercial traction; with 1-10 employees and only $250,000 in disclosed seed funding (May 2015), BioViva functions as a research-stage development platform rather than a commercial biotech. Capital is being solicited through a direct investor form on the company website, with no institutional investors, licensing deals, or partnerships documented.
BioViva firmographics
Firmographics- Name
- BioViva
- Legal name
- BioViva USA Inc
- Website
- https://bioviva-science.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioViva is a Seattle-based, privately held biotechnology company developing AAV and CMV gene therapy platforms to treat age-related diseases including dementia, heart disease, and frailty, while pursuing licensing of its IP and operating the CodeKeeper gene therapy database.
- Ownership category
- akta.pro rank
BioViva industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industry
- Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
Keywords
Where BioViva is headquartered
LocationHeadquarters
- HQ city
- Bainbridge Island
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioViva business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Gene Therapy Drug Development and Licensing: BioViva focuses on advancing the state-of-the-art of gene therapy to develop and license drugs. The company has one patent granted and several pending in the AAV and CMV gene therapy spaces. Initial targets include age-related disorders like dementia, frailty, and type 2 diabetes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
BioViva product offering
Product offeringCore offering
BioViva develops regenerative gene therapy platforms—AAV and CMV viral vector systems—to deliver therapeutic genes that target the cellular causes of aging-associated diseases such as heart disease, dementia, diabetes, and frailty. The company maintains a pipeline of specific gene therapy candidates (telomerase, klotho, follistatin, PGC-1a, FGF21) and offers CodeKeeper™, an open-access gene therapy database for researchers and institutions. BioViva focuses on developing and licensing these therapies rather than directly dispensing them at scale today.
Product overview
BioViva is a biotechnology company developing gene therapies to treat aging-associated diseases. The company operates two core gene therapy platforms: the patented AAV (Adeno-Associated Virus) gene therapy platform and the patent-pending CMV (Cytomegalovirus) gene therapy platform, which supports larger genetic payloads for complex disease treatment. BioViva's therapeutic pipeline includes specific gene therapies targeting telomerase (hTERT), klotho, follistatin, PGC-1a, and FGF21, each addressing different hallmarks of aging. Additionally, the company offers CodeKeeper™, an open-access gene therapy database for researchers and institutions. The company is led by CEO Liz Parrish and is headquartered in Seattle, WA.
Differentiator
Problem solved
Functional benefit
Products and services
- AAV Gene Therapy Platform Adeno-associated virus (AAV) gene therapy platform that uses a natural viral vector to deliver therapeutic genes into human cells for the treatment of aging-associated diseases. Has an excellent safety profile in research studies and trials and is one of the most widely used gene therapy vectors.
- CMV Gene Therapy Platform Patent-pending cytomegalovirus (CMV) gene delivery platform with the capacity to support larger genetic loads than AAV vectors and incorporate multiple genes per treatment. In initial animal studies, CMV treatment extended lifespan by over 41% and it is being utilized as part of multiple immunotherapies including treatments for cancer, AIDS, and malaria.
- CodeKeeper™ Open-access database for gene therapy designed for anyone interested in understanding or contributing to the state-of-the-art in gene therapy. Advanced tools are available for universities, companies, and independent researchers.
- Telomerase (hTERT) Gene Therapy Gene therapy candidate targeting telomere attrition—one of the hallmarks of aging—by delivering telomerase (hTERT) to lengthen telomeres and prevent cellular aging and replicative arrest.
- Klotho Gene Therapy Gene therapy candidate targeting the klotho gene. Klotho has been shown to reverse β-Amyloid plaques associated with Alzheimer's disease and protect against cognitive deficits.
- Follistatin Gene Therapy Gene therapy candidate addressing sarcopenia (muscle degeneration during aging) by inhibiting myostatin via follistatin protein delivery to help maintain muscle mass during aging. Extended mouse lifespan by 32% in studies.
- PGC-1a Gene Therapy Gene therapy candidate targeting mitochondrial function decline during the aging process. May benefit Alzheimer's disease patients by improving mitochondrial function, the cell's energy generation system, and reducing oxidative stress.
- FGF21 Gene Therapy Gene therapy candidate targeting metabolic dysfunction associated with aging.
Quantifiable outcome
- Over 41% lifespan extension in animal studies with CMV vector
- +4 more outcomes
Companies that use BioViva
Customer profileSegments3 records
Ideal customer profiles3 records
BioViva technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
BioViva partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights4 records
BioViva competitors and assessment
Company assessmentDirect peers
- Altos Labs: Well-capitalized biotech focused on cellular rejuvenation programming to reverse diseases of aging. Directly competes with BioViva in targeting the biology of aging and has overlapping gene therapy / cell-engineering ambitions.
- BioAge Labs: Clinical-stage biotech discovering and developing therapeutics that target the molecular mechanisms of aging. Competes with BioViva in aging-focused drug development and shares the longevity thesis.
- Unity Biotechnology: Clinical-stage biotech developing senolytic medicines to treat aging-related diseases. Closely comparable to BioViva's mission of clearing or reversing cellular aging drivers.
- Oisín Biotechnologies: Longevity biotech founded by Matthew Scholz (BioViva advisor) developing gene therapy to clear senescent cells. Direct overlap with BioViva in gene-therapy-driven longevity interventions.
- Libella Gene Therapeutics: Gene therapy company developing a telomerase-based treatment for age-related diseases. Closely comparable to BioViva's hTERT program in target biology and delivery approach.
- Turn Biotechnologies: Biotech developing mRNA-based gene therapy to re-program cells and reverse aging-related cellular damage. Comparable regenerative-medicine approach targeting aging hallmarks.
- Life Biosciences: Longevity biotech pursuing multiple gene-therapy and small-molecule programs against the hallmarks of aging. Shares BioViva's broad multi-modality longevity strategy.
Broad incumbents
- Calico Life Sciences: Alphabet-backed R&D organization focused on aging biology and age-related diseases. Operates broadly in the same longevity space as BioViva with vastly greater resources and is a key reference competitor.
Emerging players
- Rejuvenate Bio: George Church-spinout using gene therapy to treat aging and age-related diseases. Direct relevance given shared scientific lineage with BioViva's advisor and overlapping AAV-based approach.
Others
- SENS Research Foundation: Non-profit research foundation co-founded by BioViva advisor Aubrey de Gray, focused on rejuvenation biotech. Comparable as a thought-leader and ecosystem partner in the longevity field BioViva targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
BioViva social profiles
Digital presenceBioViva financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioViva leadership team
Management profileNumber of profiles
Profiles5 records
BioViva funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioViva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioViva
What does BioViva do?
BioViva develops regenerative gene therapy platforms—AAV and CMV viral vector systems—to deliver therapeutic genes that target the cellular causes of aging-associated diseases such as heart disease, dementia, diabetes, and frailty. The company maintains a pipeline of specific gene therapy candidates (telomerase, klotho, follistatin, PGC-1a, FGF21) and offers CodeKeeper™, an open-access gene therapy database for researchers and institutions. BioViva focuses on developing and licensing these therapies rather than directly dispensing them at scale today.
Is BioViva a public or private company?
BioViva is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioViva founded?
BioViva was founded in 2015. It employs 1 to 10 people.
Where is BioViva based?
BioViva is headquartered in Bainbridge Island, United States, in the North America region.
How does BioViva make money?
One revenue line is on record: gene Therapy Drug Development and Licensing.
Who are BioViva's main competitors?
Direct peers on record are Altos Labs, BioAge Labs, Unity Biotechnology, Oisín Biotechnologies, Libella Gene Therapeutics, Turn Biotechnologies and Life Biosciences. Calico Life Sciences is listed as a broad incumbent. Rejuvenate Bio is listed as an emerging player. SENS Research Foundation is listed as an others.
Does BioViva have an API?
No public API is recorded for BioViva.
What industry is BioViva in?
BioViva's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies. Its NAICS code is 325414 and its SIC code is 2836.